Key Points
- Insider sale: Jeremy Hayden sold 13,761 shares at $3.55 on April 6 for $48,851.55 under a pre-arranged Rule 10b5-1 plan, lowering his stake by 3.59% to 369,770 shares (~$1.31M).
- Recent results show a beat on the quarter (EPS of ($0.08) vs. consensus ($0.15)) with $20.39M revenue, but the company remains unprofitable (net margin -49.67%) and the stock trades around $3.50 with a market cap of about $189M.
- Analyst sentiment is mixed—average rating is Hold with an average target of $8.31 (individual targets $6.50–$11.00)—and institutional investors own roughly 55.5% of the shares.
Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) CFO James Rodberg sold 7,231 shares of Sight Sciences stock in a transaction on Monday, April 6th. The shares were sold at an average price of $3.55, for a total transaction of $25,670.05. Following the completion of the sale, the chief financial officer directly owned 230,939 shares in the company, valued at $819,833.45. This represents a 3.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
James Rodberg also recently made the following trade(s):
- On Friday, January 16th, James Rodberg sold 2,616 shares of Sight Sciences stock. The shares were sold at an average price of $6.62, for a total transaction of $17,317.92.
Sight Sciences Price Performance
Sight Sciences stock opened at $3.50 on Friday. The company's fifty day moving average price is $4.62 and its 200 day moving average price is $5.73. Sight Sciences, Inc. has a 1 year low of $2.14 and a 1 year high of $9.24. The stock has a market capitalization of $189.04 million, a P/E ratio of -4.67 and a beta of 2.50. The company has a debt-to-equity ratio of 0.63, a quick ratio of 9.52 and a current ratio of 10.22.
Sight Sciences (NASDAQ:SGHT - Get Free Report) last released its quarterly earnings results on Wednesday, March 4th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.07. Sight Sciences had a negative net margin of 49.67% and a negative return on equity of 55.72%. The firm had revenue of $20.39 million for the quarter, compared to analysts' expectations of $20.35 million. As a group, equities research analysts anticipate that Sight Sciences, Inc. will post -0.99 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Sight Sciences
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Americana Partners LLC boosted its stake in Sight Sciences by 42.4% during the 3rd quarter. Americana Partners LLC now owns 1,229,819 shares of the company's stock worth $4,231,000 after purchasing an additional 365,901 shares during the last quarter. Alliancebernstein L.P. raised its holdings in shares of Sight Sciences by 5.5% during the 3rd quarter. Alliancebernstein L.P. now owns 34,380 shares of the company's stock worth $118,000 after acquiring an additional 1,800 shares during the period. Kemnay Advisory Services Inc. purchased a new position in shares of Sight Sciences during the 4th quarter worth $107,000. O Shaughnessy Asset Management LLC purchased a new position in shares of Sight Sciences during the 4th quarter worth $81,000. Finally, XTX Topco Ltd purchased a new position in shares of Sight Sciences during the 2nd quarter worth $67,000. Institutional investors and hedge funds own 55.51% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts recently issued reports on SGHT shares. UBS Group dropped their price target on shares of Sight Sciences from $12.00 to $11.00 and set a "buy" rating on the stock in a research note on Friday, March 6th. Stifel Nicolaus lifted their target price on shares of Sight Sciences from $6.00 to $8.00 and gave the stock a "buy" rating in a research note on Monday, March 2nd. Piper Sandler set a $9.00 target price on shares of Sight Sciences in a research note on Monday, January 5th. Raymond James Financial set a $9.00 target price on shares of Sight Sciences in a research note on Monday, January 5th. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Sight Sciences in a research note on Monday, December 29th. Five research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Sight Sciences presently has an average rating of "Hold" and a consensus target price of $8.31.
View Our Latest Report on Sight Sciences
Sight Sciences Company Profile
(
Get Free Report)
Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company's flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye's natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.
Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
